News

ThermoDox is a proprietary heat-activated liposomal encapsulation of Doxorubicin. Celsion said that ThermoDox is currently being evaluated under a special protocol assessment with the US Food and Drug

As per the terms of the non-exclusive agreement, Boehringer Ingelheim will have access to VTU Technology’s ready-to-use high expression Pichia system in close collaboration with the VTU team

Compound libraries will be screened at the Michigan High Throughput Screening Center under the direction of Robert Kilkuskie. The company said that the antibodies developed in this program

Lannett posted a net loss of $403.561 for the first quarter 2010, or $0.02 loss per diluted share, compared to net loss of $2.86m, or $0.11 per diluted

Catalent said that this expansion will enable the company to offer formulation development and optimisation services in its Winchester, Kentucky facility and complements that site’s existing pilot scale

The $244,479 grant includes the development of vaccines to prevent infections by Yersinia, Salmonella and Staphylococcus bacteria. The QTDP program, included as part of the Patient Protection and

ASA404 is a tumor-vascular disrupting agent (tumor-VDA). Novartis signed an exclusive licensing agreement with Antisoma for the worldwide rights to ASA404 in April 2007. In March 2010, ASA404

Sage Bionetworks said that a team of network biologists, systems biologists, statistical geneticists and computational biologists use coherent datasets containing clinical, genetic and molecular layers of information to

AOBO is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialisation of prescription and OTC products. AOBO chairman and CEO Tony Liu said that